159 related articles for article (PubMed ID: 10592100)
21. 18F-radiopharmacokinetics of [18F]-5-fluorouracil in a mouse bearing two colon tumors with a different 5-fluorouracil sensitivity: a study for a correlation with oncological results.
Visser GW; van der Wilt CL; Wedzinga R; Peters GJ; Herscheid JD
Nucl Med Biol; 1996 Apr; 23(3):333-42. PubMed ID: 8782245
[TBL] [Abstract][Full Text] [Related]
22. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
23. Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.
Chen TL; Erlichman C
Cancer Chemother Pharmacol; 1992; 30(5):370-6. PubMed ID: 1380407
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
[TBL] [Abstract][Full Text] [Related]
25. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles.
Li S; Wang A; Jiang W; Guan Z
BMC Cancer; 2008 Apr; 8():103. PubMed ID: 18412945
[TBL] [Abstract][Full Text] [Related]
27. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
28. Elucidation of underlying molecular mechanism of 5-Fluorouracil chemoresistance and its restoration using fish oil in experimental colon carcinoma.
Rani I; Kumar S; Sharma B; Prasad R; Kaur S; Sharma P; Agnihotri N
Mol Cell Biochem; 2021 Mar; 476(3):1517-1527. PubMed ID: 33392922
[TBL] [Abstract][Full Text] [Related]
29. 19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine.
Holland SK; Bergman AM; Zhao Y; Adams ER; Pizzorno G
Magn Reson Med; 1997 Dec; 38(6):907-16. PubMed ID: 9402191
[TBL] [Abstract][Full Text] [Related]
30. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
[TBL] [Abstract][Full Text] [Related]
31. Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels.
Grem JL; Fischer PH
Cancer Res; 1986 Dec; 46(12 Pt 1):6191-9. PubMed ID: 2946402
[TBL] [Abstract][Full Text] [Related]
32. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
Guichard SM; Macpherson JS; Mayer I; Reid E; Muir M; Dodds M; Alexander S; Jodrell DI
Eur J Cancer; 2008 Jan; 44(2):310-7. PubMed ID: 18077151
[TBL] [Abstract][Full Text] [Related]
33. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.
Jiang H; Lu J; Jiang J; Hu P
J Clin Pharmacol; 2004 Nov; 44(11):1260-72. PubMed ID: 15496644
[TBL] [Abstract][Full Text] [Related]
34. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells.
van der Wilt CL; Smid K; Aherne GW; Noordhuis P; Peters GJ
Eur J Cancer; 1997 Mar; 33(3):471-8. PubMed ID: 9155534
[TBL] [Abstract][Full Text] [Related]
35. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil.
Derissen EJ; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2015 Jun; 110():58-66. PubMed ID: 25804433
[TBL] [Abstract][Full Text] [Related]
36. 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice.
Innocenti F; Danesi R; Bocci G; Natale G; Del Tacca M
Toxicol Appl Pharmacol; 2005 Mar; 203(2):106-13. PubMed ID: 15710171
[TBL] [Abstract][Full Text] [Related]
37. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
Bocci G; Danesi R; Allegrini G; Innocenti F; Di Paolo A; Falcone A; Conte PF; Del Tacca M
Eur J Clin Pharmacol; 2002 Dec; 58(9):593-5. PubMed ID: 12602342
[TBL] [Abstract][Full Text] [Related]
38. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
[TBL] [Abstract][Full Text] [Related]
39. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine.
Darnowski JW; Handschumacher RE
Cancer Res; 1985 Nov; 45(11 Pt 1):5364-8. PubMed ID: 4053009
[TBL] [Abstract][Full Text] [Related]
40. 5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo.
Tausch-Treml R; Baumgart F; Ziessow D; Köpf-Maier P
Cancer Chemother Pharmacol; 1996; 37(3):259-65. PubMed ID: 8529287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
